Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

Vaccines are designed to guard babies, toddlers, and older children against a whole range of serious and potentially deadly ...

The French drugmaker said it had entered a mandate with an “investment service provider”, with the purchase occurring between ...

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good ...

Government faces healthcare crisis as new physician output drops significantly in Korea New challenges arise as disruptions in medical education threaten Koreas healthcare future.

One Zelienople child survived a serious health scare after coming down with respiratory syncytial virus in late January. The ...

A vaccine designed to help protect babies from the respiratory syncytial virus (RSV) is now free during pregnancy. RSV is the ...

L'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.

The one-off therapy, nirsevimab, is designed to protect again illness from respiratory syncytial virus (RSV) which can be deadly for infants. RSV is one of a number of viruses that surge in winter ...

Sanofi’s fiscal year 2024 results were in line with expectations, with a noteworthy performance in their Vaccines division, particularly driven by Beyfortus. This offset a slight ...

A successful example of these technologies coming together is Sanofi and AstraZeneca’s Beyfortus (nirsevimab-alip), an anti-RSV monoclonal antibody approved for the prevention of RSV in infants.

Nirsevimab (Beyfortus) immunization is for infants under 8 months of age during RSV season. It is also for some children age 8 through 19 months who are at increased risk for severe RSV disease and ...